ATE230988T1 - Die verwendung von ondansetron zur herstellung eines medikamentes zur behandlung von tremor - Google Patents

Die verwendung von ondansetron zur herstellung eines medikamentes zur behandlung von tremor

Info

Publication number: ATE230988T1
Authority: AT; Austria
Prior art keywords: treatment; ondansetron; tremor; medication; production
Prior art date: 1995-09-18

Application number

AT96929991T

Other languages

English (en)

Inventor

George Peter Arthur Rice

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-09-18

Filing date

1996-09-16

Publication date

2003-02-15

1995-09-18 Priority claimed from GBGB9519029.4A external-priority patent/GB9519029D0/en

1995-09-18 Priority claimed from GBGB9519021.1A external-priority patent/GB9519021D0/en

1996-09-16 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2003-02-15 Application granted granted Critical

2003-02-15 Publication of ATE230988T1 publication Critical patent/ATE230988T1/de

Links

FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
229960005343 ondansetron Drugs 0.000 title 1
229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 abstract 1
208000012661 Dyskinesia Diseases 0.000 abstract 1
239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Orthopedics, Nursing, And Contraception (AREA)
Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)

AT96929991T 1995-09-18 1996-09-16 Die verwendung von ondansetron zur herstellung eines medikamentes zur behandlung von tremor ATE230988T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9519029.4A GB9519029D0 (en)	1995-09-18	1995-09-18	Medicaments
GBGB9519021.1A GB9519021D0 (en)	1995-09-18	1995-09-18	Medicaments
PCT/CA1996/000616 WO1997010823A1 (en)	1995-09-18	1996-09-16	5-ht3 receptor antagonists for dyskinesia

Publications (1)

Publication Number	Publication Date
ATE230988T1 true ATE230988T1 (de)	2003-02-15

Family

ID=26307778

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96929991T ATE230988T1 (de)	1995-09-18	1996-09-16	Die verwendung von ondansetron zur herstellung eines medikamentes zur behandlung von tremor

Country Status (19)

Country	Link
EP (1)	EP0851756B1 (de)
JP (1)	JP3411292B2 (de)
KR (1)	KR19990045728A (de)
CN (1)	CN1201390A (de)
AT (1)	ATE230988T1 (de)
AU (1)	AU6921196A (de)
BR (1)	BR9610526A (de)
CA (1)	CA2231887A1 (de)
CZ (1)	CZ82698A3 (de)
DE (1)	DE69625819T2 (de)
EA (1)	EA199800204A1 (de)
ES (1)	ES2191106T3 (de)
HU (1)	HUP9900606A2 (de)
IL (1)	IL123536A0 (de)
IS (1)	IS4686A (de)
NO (1)	NO981188L (de)
PL (1)	PL325560A1 (de)
TR (1)	TR199800488T1 (de)
WO (1)	WO1997010823A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003100091A1 (en) *	2002-05-24	2003-12-04	Epidauros Biotechnologie Ag	Means and methods for improved treatment using 'setrones'

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8808433D0 (en) *	1988-04-11	1988-05-11	Merck Sharp & Dohme	Therapeutic agents
US5140034A (en) *	1989-03-14	1992-08-18	Merck Sharp & Dohme Ltd.	Five-membered ring systems with bonded imidazolyl ring substituents
DE69026759D1 (de) *	1989-07-03	1996-06-05	Yoshitomi Pharmaceutical	Benzazin-Verbindungen und deren pharmazeutische Verwendungen
FR2674853B1 (fr) *	1991-04-03	1995-01-20	Synthelabo	Derives de piperidinylguanidine, leur preparation et leur application en therapeutique.
FR2693194B1 (fr) *	1992-07-03	1994-09-23	Synthelabo	Dérivés d'alcanecarboxamide, leur préparation et leur application thérapeutique.
FR2696177B1 (fr) *	1992-09-28	1995-05-12	Synthelabo	Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
FR2710915B1 (fr) *	1993-10-04	1995-11-24	Synthelabo	Dérivés de pipéridine, leur préparation et leur utilisation en thérapeutique.
FR2731708B1 (fr) *	1995-03-13	1997-04-30	Synthelabo	Derives de piperidine, leur procede de preparation et leur application en therapeutique

1996
- 1996-09-16 HU HU9900606A patent/HUP9900606A2/hu unknown
- 1996-09-16 BR BR9610526A patent/BR9610526A/pt not_active Application Discontinuation
- 1996-09-16 DE DE69625819T patent/DE69625819T2/de not_active Expired - Fee Related
- 1996-09-16 CN CN96198141A patent/CN1201390A/zh active Pending
- 1996-09-16 AU AU69211/96A patent/AU6921196A/en not_active Abandoned
- 1996-09-16 TR TR1998/00488T patent/TR199800488T1/xx unknown
- 1996-09-16 AT AT96929991T patent/ATE230988T1/de not_active IP Right Cessation
- 1996-09-16 CA CA002231887A patent/CA2231887A1/en not_active Abandoned
- 1996-09-16 IL IL12353696A patent/IL123536A0/xx unknown
- 1996-09-16 PL PL96325560A patent/PL325560A1/xx unknown
- 1996-09-16 EA EA199800204A patent/EA199800204A1/ru unknown
- 1996-09-16 EP EP96929991A patent/EP0851756B1/de not_active Expired - Lifetime
- 1996-09-16 JP JP51226097A patent/JP3411292B2/ja not_active Expired - Fee Related
- 1996-09-16 ES ES96929991T patent/ES2191106T3/es not_active Expired - Lifetime
- 1996-09-16 WO PCT/CA1996/000616 patent/WO1997010823A1/en not_active Ceased
- 1996-09-16 CZ CZ98826A patent/CZ82698A3/cs unknown
- 1996-09-16 KR KR1019980701969A patent/KR19990045728A/ko not_active Withdrawn
1998
- 1998-03-09 IS IS4686A patent/IS4686A/is unknown
- 1998-03-17 NO NO981188A patent/NO981188L/no unknown

Also Published As

Publication number	Publication date
JP3411292B2 (ja)	2003-05-26
PL325560A1 (en)	1998-08-03
CN1201390A (zh)	1998-12-09
IS4686A (is)	1998-03-09
EP0851756A1 (de)	1998-07-08
KR19990045728A (ko)	1999-06-25
MX9802001A (es)	1998-10-31
WO1997010823A1 (en)	1997-03-27
IL123536A0 (en)	1998-10-30
HUP9900606A2 (hu)	2000-03-28
CA2231887A1 (en)	1997-03-27
JPH10511986A (ja)	1998-11-17
CZ82698A3 (cs)	1998-08-12
TR199800488T1 (xx)	1998-05-21
NO981188D0 (no)	1998-03-17
NO981188L (no)	1998-05-13
AU6921196A (en)	1997-04-09
DE69625819D1 (de)	2003-02-20
EA199800204A1 (ru)	1998-10-29
BR9610526A (pt)	1999-07-06
EP0851756B1 (de)	2003-01-15
ES2191106T3 (es)	2003-09-01
DE69625819T2 (de)	2003-11-06

Legal Events

Date	Code	Title	Description
2003-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE234095T1 (de)	2003-03-15	Produkt enthaltend rapamycin oder ausgewählte derivate und einen nmda- oder ampa-antagonisten zur verwendung für die behandlung von epilepsie oder morbus huntington, und die verwendung von rapamycin oder von ausgewählten derivaten für die herstellung eines medikaments für die behandlung von epilepsie oder morbus huntington.
NO20050408L (no)	1997-12-08	Nye camptothecinderivater (CPT-11) og beslektede forbindelser, samt fremgangsmate for fremstilling derav
FI980862A0 (fi)	1998-04-17	Kiraalisia metyylifenyylioksatsolidinoneja
ATE284693T1 (de)	2005-01-15	Verwendung von dopamin-d 3-rezeptorantagonisten zur herstellung von arzneimittel für die behandlung von nierenfunktionsstörungen
HUP9802762A2 (hu)	1999-10-28	Difenil-metilén-piperidin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
DE69506686D1 (de)	1999-01-28	Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase
ATE200423T1 (de)	2001-04-15	Verwendung von 1-(2-naphtylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode
PL350568A1 (en)	2002-12-16	N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
ATE232387T1 (de)	2003-02-15	Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes
DE50010234D1 (de)	2005-06-09	Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE230988T1 (de)	2003-02-15	Die verwendung von ondansetron zur herstellung eines medikamentes zur behandlung von tremor
DE69430427D1 (de)	2002-05-23	Verwendung von ropivacaine zur herstellung eines analgetikums mit minimaler motorischer blockade
DE69606777D1 (de)	2000-03-30	Naphthamidderivate von 3-beta-amino azabicyclooctan oder nonan als antipsychotische arzneimittel
DE69620786D1 (de)	2002-05-23	Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie
ATE192650T1 (de)	2000-05-15	Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE186640T1 (de)	1999-12-15	Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen
DE69614838D1 (de)	2001-10-04	Verfahren zur herstellung von anhydroecgonin-estern
ATE265999T1 (de)	2004-05-15	Neuer ltb4-antagonist, verfahren zu dessen herstellung und dessen verwendung als arzneimittel
ATE345124T1 (de)	2006-12-15	Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia
SE9501773D0 (sv)	1995-05-15	New use